echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: A new follow-up study shows that one in ten patients with new crowns has neurological disorders

    Neurology: A new follow-up study shows that one in ten patients with new crowns has neurological disorders

    • Last Update: 2021-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Various studies have found that the incidence of new coronavirus infection in patients with the nervous system is between 3.5 and 84%.
    and COVID-19-related neurological disorders include encephalopathy, aloofness, dizziness, headache, stroke, epilepsy, acute necrotological encephalopathy, isodemic isomorthic brain injury, encephalitis and demyelinative multiple neuropathy.
    , however, differences in methodology, neurological event definition, queue size, and determination led to differences in reporting.
    addition, there is little forward-looking data to evaluate neurological outcomes in patients with COVID-19.
    National University of New York, Jennifer A. Frontera et al. conducted a forward-looking, multi-center, observational study based on adults who were hospitalized continuously in the New York City metropolitan area, and looked forward to the incidence of specific neurological disorders, comparing the similarity and differences between COVID-19 patients with or without neurological symptoms, as well as related complications and discharges.
    further analysis, they also compared neurological disorders in PATIENT-19 patients before and after hospitalization.
    results showed that of the 4,491 COVID-19 patients hospitalized during the study period, 606 (13.5%) developed new neurological disorders within 2 days of the middle of COVID-19 symptoms.
    most common diagnoses were toxic/metabolic encephalopathy (6.8 per cent), epilepsy (1.6 per cent), stroke (1.9 per cent) and hypoxia/isomorric injury (1.4 per cent).
    no patients showed meningitis/encephalitis or myelitis/spinal corditis with SARS-CoV-2 infection, and all 18 CSF specimens were SARS-CoV-2 reverse transcriptase PCR-negative.
    patients with neurological disorders were mostly elderly, male, white, hypertension, diabetes, intive patients, and the continuous organ failure assessment (SOFA) score was higher (average P<0.05).
    the risk of death in hospital for patients with COVID-19 neurological disorders (HR=1.38, P<0.001) and reduced likelihood of returning home (HR 0.72, P<001) after adjusting age, gender, SOFA score, intumberation, medical history, medical complications, medication and comfort care status.
    significance of this study is that 13.5 percent of COVID-19 patients were found to have detected neurological disorders, which were associated with an increased risk of death in hospital and a reduced likelihood of returning home from the hospital.
    many of the observed neurological disorders may stem from the after-effects of severe systemic diseases.
    origin: A Prospective Study of Neurologic Disorders in Student Patients With COVID-19 in New York City, Jennifer A. Frontera, Sakinah Sabadia, et al. Neurology Jan 2021, 96 (4) e575-e586; DOI: 10.1212/WNL.00000000000010979Freeman Source: MedSci Original Copyright Notice: All noted on this website "Source: Metz Medicine" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.